The software of life is how Moderna Inc. CEO Stephane Bancel describes messenger RNA (mRNA), which is at the core of the company’s drug development process.
The U.S. Food and Drug Administration granted Fast Track designation for mRNA-3927, Moderna Inc.’s investigational messenger RNA therapeutic for propionic acidemia (PA).
